Skip to main content
Premium Trial:

Request an Annual Quote

BioCheetah Inks Deal With Nippon Kayaku to Sell VecanDx Bladder Cancer Test in Japan

NEW YORK — Cancer diagnostics firm BioCheetah said Friday that it has entered a licensing and commercialization agreement with Nippon Kayaku for its VecanDx bladder cancer diagnostic.

Under the agreement, Singapore-based BioCheetah will give Tokyo-based Nippon Kayaku exclusive rights to develop and market VecanDx in Japan, with BioCheetah receiving upfront and milestone payments.

Nippon Kayaku will be responsible for clinical trials, regulatory applications, and sales and distribution of the test in Japan. BioCheetah will continue to complete clinical trials for the test in Singapore, France, and China.

VecanDx is an immunoassay intended for use in individuals with hematuria or a history of bladder cancer. It measures the expression of five proteins in urine and combines those protein measurements into a risk score assessing the presence or absence of bladder cancer.